{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:21:24Z","timestamp":1772616084304,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11102-021-01168-x","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T17:02:52Z","timestamp":1624986172000},"page":"955-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas"],"prefix":"10.1007","volume":"24","author":[{"given":"Ji Yong","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonsuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Ram","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-3171","authenticated-orcid":false,"given":"Hee Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Youl","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"issue":"5","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516\u2013524. https:\/\/doi.org\/10.1001\/jama.2016.19699","journal-title":"JAMA"},{"issue":"4","key":"1168_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","volume":"16","author":"M Gruppetta","year":"2013","unstructured":"Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16(4):545\u2013553. https:\/\/doi.org\/10.1007\/s11102-012-0454-0","journal-title":"Pituitary"},{"issue":"9","key":"1168_CR3","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","volume":"95","author":"A Raappana","year":"2010","unstructured":"Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992\u20132007. J Clin Endocrinol Metab 95(9):4268\u20134275. https:\/\/doi.org\/10.1210\/jc.2010-0537","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1168_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"1168_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3803\/EnM.2020.35.2.237","volume":"35","author":"SO Chin","year":"2020","unstructured":"Chin SO (2020) Epidemiology of functioning pituitary adenomas. Endocrinol Metab (Seoul) 35(2):237\u2013242. https:\/\/doi.org\/10.3803\/EnM.2020.35.2.237","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"1168_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1168_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R et al (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60(4):698\u2013705. https:\/\/doi.org\/10.1210\/jcem-60-4-698","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485\u2013534. https:\/\/doi.org\/10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"issue":"3","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/14656566.1.3.555","volume":"1","author":"A Colao","year":"2000","unstructured":"Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1(3):555\u2013574. https:\/\/doi.org\/10.1517\/14656566.1.3.555","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"1168_CR10","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518\u20132522. https:\/\/doi.org\/10.1210\/jcem.84.7.5810","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1168_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356(1):39\u201346. https:\/\/doi.org\/10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"issue":"4","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4065\/74.4.371","volume":"74","author":"LH Ling","year":"1999","unstructured":"Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK (1999) Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson\u2019s disease. Mayo Clin Proc 74(4):371\u2013375. https:\/\/doi.org\/10.4065\/74.4.371","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1168_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-020-0507-8","volume":"20","author":"A Budayr","year":"2020","unstructured":"Budayr A, Tan TC, Lo JC, Zaroff JG, Tabada GH, Yang J et al (2020) Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocr Disord 20(1):25. https:\/\/doi.org\/10.1186\/s12902-020-0507-8","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J et al (2020) Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. 105(3):e95\u2013e106. https:\/\/doi.org\/10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z et al (2019) Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 104(7):2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428\u20132436. https:\/\/doi.org\/10.1210\/jc.2008-2103","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW (2011) Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14(3):222\u2013230. https:\/\/doi.org\/10.1007\/s11102-010-0283-y","journal-title":"Pituitary"},{"issue":"4","key":"1168_CR18","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2011.1.FOCUS10317","volume":"30","author":"CP Hofstetter","year":"2011","unstructured":"Hofstetter CP, Shin BJ, Mubita L, Huang C, Anand VK, Boockvar JA et al (2011) Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus 30(4):E10. https:\/\/doi.org\/10.3171\/2011.1.FOCUS10317","journal-title":"Neurosurg Focus"},{"issue":"1","key":"1168_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R et al (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11\u201318. https:\/\/doi.org\/10.1530\/EJE-07-0248","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1168_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3803\/EnM.2014.29.3.280","volume":"29","author":"Y Lee","year":"2014","unstructured":"Lee Y, Ku CR, Kim EH, Hong JW, Lee EJ, Kim SH (2014) Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol Metab (Seoul) 29(3):280\u2013292. https:\/\/doi.org\/10.3803\/EnM.2014.29.3.280","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1168_CR21","doi-asserted-by":"publisher","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 33(4):610\u2013617; Discussion 7\u20138. https:\/\/doi.org\/10.1227\/00006123-199310000-00008.","DOI":"10.1227\/00006123-199310000-00008"},{"key":"1168_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.wneu.2016.08.088","volume":"96","author":"S Dhandapani","year":"2016","unstructured":"Dhandapani S, Singh H, Negm HM, Cohen S, Anand VK, Schwartz TH (2016) Cavernous sinus invasion in pituitary adenomas: systematic review and pooled data meta-analysis of radiologic criteria and comparison of endoscopic and microscopic surgery. World Neurosurg 96:36\u201346. https:\/\/doi.org\/10.1016\/j.wneu.2016.08.088","journal-title":"World Neurosurg"},{"issue":"2","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","volume":"97","author":"AP Amar","year":"2002","unstructured":"Amar AP, Couldwell WT, Chen JC, Weiss MH (2002) Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 97(2):307\u2013314. https:\/\/doi.org\/10.3171\/jns.2002.97.2.0307","journal-title":"J Neurosurg"},{"issue":"1","key":"1168_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","volume":"23","author":"EV Varlamov","year":"2020","unstructured":"Varlamov EV, Hinojosa-Amaya JM, Fleseriu M (2020) Magnetic resonance imaging inthe management of prolactinomas; a review of the evidence. Pituitary 23(1):16\u201326. https:\/\/doi.org\/10.1007\/s11102-019-01001-6","journal-title":"Pituitary"},{"issue":"4","key":"1168_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","volume":"64","author":"E Delgrange","year":"2006","unstructured":"Delgrange E, Duprez T, Maiter D (2006) Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf) 64(4):456\u2013462. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02493.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5816","key":"1168_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/bmj.2.5816.743","volume":"2","author":"L Varga","year":"1972","unstructured":"Varga L, Lutterbeck PM, Pryor JS, Wenner R, Erb H (1972) Suppression of puerperal lactation with an ergot alkaloid: a double-blind study. Br Med J 2(5816):743\u2013744. https:\/\/doi.org\/10.1136\/bmj.2.5816.743","journal-title":"Br Med J"},{"issue":"14","key":"1168_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea Cabergoline Comparative Study Group. N Engl J Med. 331(14):904\u2013909. https:\/\/doi.org\/10.1056\/NEJM199410063311403","journal-title":"N Engl J Med."},{"issue":"1","key":"1168_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43\u201351. https:\/\/doi.org\/10.1210\/jc.2009-1238","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1168_CR29","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1210\/clinem\/dgaa744","volume":"106","author":"K Kim","year":"2021","unstructured":"Kim K, Park YW, Kim D, Ahn SS, Moon JH, Kim EH et al (2021) Biochemical remission after cabergoline withdrawal in hyperprolactinemic patients with visible remnant pituitary adenoma. J Clin Endocrinol Metab 106(2):e615\u2013e624. https:\/\/doi.org\/10.1210\/clinem\/dgaa744","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1168_CR30","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/cen.13339","volume":"86","author":"C Bulwer","year":"2017","unstructured":"Bulwer C, Conn R, Shankar A, Ferrau F, Kapur S, Ederies A et al (2017) Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clin Endocrinol (Oxf) 86(6):862\u2013864. https:\/\/doi.org\/10.1111\/cen.13339","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1168_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01478-0","author":"G Beccuti","year":"2020","unstructured":"Beccuti G, Guaraldi F, Natta G, Cambria V, Prencipe N, Cicolin A et al (2020) Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-020-01478-0","journal-title":"J Endocrinol Invest"},{"key":"1168_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fendo.2015.00085","volume":"6","author":"MH Almalki","year":"2015","unstructured":"Almalki MH, Alzahrani S, Alshahrani F, Alsherbeni S, Almoharib O, Aljohani N et al (2015) Managing Prolactinomas during Pregnancy. Front Endocrinol (Lausanne) 6:85. https:\/\/doi.org\/10.3389\/fendo.2015.00085","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1168_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci M, Quinones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14(1):68\u201374. https:\/\/doi.org\/10.1007\/s11102-010-0261-4","journal-title":"Pituitary"},{"key":"1168_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220971","author":"N Mohan","year":"2017","unstructured":"Mohan N, Chia YY, Goh GH, Ting E, Teo K, Yeo TT (2017) Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2017-220971","journal-title":"BMJ Case Rep"},{"issue":"3","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N (2016) Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 175(3):R89-96. https:\/\/doi.org\/10.1530\/EJE-16-0087","journal-title":"Eur J Endocrinol"},{"key":"1168_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fendo.2018.00636","volume":"9","author":"Q Ma","year":"2018","unstructured":"Ma Q, Su J, Li Y, Wang J, Long W, Luo M et al (2018) The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol (Lausanne) 9:636. https:\/\/doi.org\/10.3389\/fendo.2018.00636","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1168_CR37","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM et al (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab. 105(3):e33\u2013e42. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"key":"1168_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01569-6","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, El-Koussy M, Widmer HR et al (2021) First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-021-01569-6","journal-title":"J Endocrinol Invest"},{"issue":"15","key":"1168_CR39","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e97","volume":"36","author":"K Park","year":"2021","unstructured":"Park K, Park KH, Park HR, Lee JM, Kim YH, Kim DY et al (2021) Long-term outcome of microscopic transsphenoidal surgery for prolactinomas as an alternative to dopamine agonists. J Korean Med Sci 36(15):e97. https:\/\/doi.org\/10.3346\/jkms.2021.36.e97","journal-title":"J Korean Med Sci"},{"issue":"7","key":"1168_CR40","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87(7):3180\u20133186. https:\/\/doi.org\/10.1210\/jcem.87.7.8645","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1168_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/a-1247-4908","volume":"129","author":"S Giese","year":"2021","unstructured":"Giese S, Nasi-Kordhishti I, Honegger J (2021) Outcomes of transsphenoidal microsurgery for prolactinomas - a contemporary series of 162 cases. Exp Clin Endocrinol Diabetes 129(3):163\u2013171. https:\/\/doi.org\/10.1055\/a-1247-4908","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1168_CR42","doi-asserted-by":"publisher","unstructured":"Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, et al (2008) Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 63(4):709\u2013718; discussion 18\u201319. https:\/\/doi.org\/10.1227\/01.NEU.0000325725.77132.90.","DOI":"10.1227\/01.NEU.0000325725.77132.90"},{"issue":"2","key":"1168_CR43","first-page":"108","volume":"58","author":"RV Randall","year":"1983","unstructured":"Randall RV, Laws ER Jr, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW (1983) Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc 58(2):108\u2013121","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1168_CR44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000180098","volume":"22","author":"G Charpentier","year":"1985","unstructured":"Charpentier G, de Plunkett T, Jedynak P, Peillon F, Le Gentil P, Racadot J et al (1985) Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors. Horm Res 22(3):222\u2013227. https:\/\/doi.org\/10.1159\/000180098","journal-title":"Horm Res"},{"issue":"1","key":"1168_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23(1):45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"key":"1168_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fendo.2020.00439","volume":"11","author":"G Zielinski","year":"2020","unstructured":"Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P (2020) Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front Endocrinol (Lausanne) 11:439. https:\/\/doi.org\/10.3389\/fendo.2020.00439","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1168_CR47","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","volume":"115","author":"H Ikeda","year":"2013","unstructured":"Ikeda H, Watanabe K, Tominaga T, Yoshimoto T (2013) Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg 115(9):1621\u20131625. https:\/\/doi.org\/10.1016\/j.clineuro.2013.02.016","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"1168_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-018-0904-4","volume":"21","author":"J Honegger","year":"2018","unstructured":"Honegger J, Grimm F (2018) The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 21(5):545\u2013555. https:\/\/doi.org\/10.1007\/s11102-018-0904-4","journal-title":"Pituitary"},{"issue":"1","key":"1168_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12020-016-1115-2","volume":"55","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW et al (2017) 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55(1):223\u2013230. https:\/\/doi.org\/10.1007\/s12020-016-1115-2","journal-title":"Endocrine"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01168-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T09:20:24Z","timestamp":1635240024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01168-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01168-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"19 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no potential conflict of interest related to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Chonnam National University Hwasun Hospital, Hwasun, Korea (Approval No. CNUHH-2020-209).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethcial approval"}}]}}